Literature DB >> 19234797

Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.

G G Neznamov1, E S Teleshova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19234797     DOI： 10.1007/s11055-009-9128-4

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN： 0097-0549


× No keyword cloud information.
  15 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  ["Fast" and "slow" components of psychotropic activity of the drugs with nootropic effects].

Authors:  G G Neznamov; S A Siuniakov; I A Davydova; E S Teleshova
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2000

3.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

4.  The course of cognitive decline in older persons: results from the longitudinal aging study amsterdam.

Authors:  Hannie C Comijs; Miranda G Dik; Dorly J H Deeg; Cees Jonker
Journal:  Dement Geriatr Cogn Disord       Date:  2004-01-20       Impact factor: 2.959

5.  Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging.

Authors:  C E Coffey; W E Wilkinson; I A Parashos; S A Soady; R J Sullivan; L J Patterson; G S Figiel; M C Webb; C E Spritzer; W T Djang
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 6.  [Diagnosis and treatment of moderate cognitive disorders in the elderly].

Authors:  O S Levin
Journal:  Zh Nevrol Psikhiatr Im S S Korsakova       Date:  2006

7.  Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

Authors:  W Danysz; C G Parsons; H J Mobius; A Stoffler; G Quack
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

8.  Classification criteria for mild cognitive impairment: a population-based validation study.

Authors:  K Ritchie; S Artero; J Touchon
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

Review 9.  Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease.

Authors:  Eva Arnáiz; Ove Almkvist
Journal:  Acta Neurol Scand Suppl       Date:  2003

Review 10.  Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia.

Authors:  David S Knopman; Bradley F Boeve; Ronald C Petersen
Journal:  Mayo Clin Proc       Date:  2003-10       Impact factor: 7.616
View more
  3 in total

1.  Five Unapproved Drugs Found in Cognitive Enhancement Supplements.

Authors:  Pieter A Cohen; Bharathi Avula; Yan Hong Wang; Igor Zakharevich; Ikhlas Khan
Journal:  Neurol Clin Pract       Date:  2021-06

Review 2.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

3.  Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation.

Authors:  Rita U Ostrovskaya; Yulia V Vakhitova; Uliyana Sh Kuzmina; Milyausha Kh Salimgareeva; Liana F Zainullina; Tatiana A Gudasheva; Vener A Vakhitov; Sergey B Seredenin
Journal:  J Biomed Sci       Date:  2014-08-06       Impact factor: 8.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.